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Background: This study compared effectiveness and acceptance of orally disintegrating 
olanzapine tablets (ODT) with standard-coated tablets (SOT) in acutely ill psychiatric patients 
admitted to psychiatric hospitals for emergency treatment.
Methods: Large, prospective, observational study at hospital emergency units across Germany 
in patients with a diagnosis or tentative diagnosis of acute schizophrenia treated with ODT or 
SOT. Clinical (CGI-S and CGI-I) outcomes, attitudes towards medication (Nursing Assessment 
of Medication Acceptance, NAMA) scale, suicidal ideation, and adverse events were assessed 
at start of treatment and after 2 weeks.
Results: Both olanzapine formulations, ODT (N = 247) and SOT (N = 207), showed similar 
effectiveness after 2 weeks. CGI-I improved in 92.1% of patients (ODT: 91.8%, SOT: 92.3%). 
In patients receiving both formulations suicidal ideations were reduced (ODT from 53.9% to 
20.6%, SOT from 51.2% to 22.7%). ODT was preferably given to severely ill (SOT: 49.8%, 
ODT: 64.4%) and aggressive patients. Adverse events were reported for 6.5% of ODT- and 
2.9% of SOT-patients. This difference was possibly caused by the characteristics of patients 
receiving ODT.
Conclusions: This non-randomized, observational study shows comparable outcomes and 
tolerability in patients treated with both olanzapine formulations. In an acute treatment setting, 
orally disintegrating tablets were preferably used for more severely ill and aggressive patients 
with low medication acceptance.
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Background
Schizophrenia and related disorders are severe, incapacitating psychiatric diseases 
that, in most cases, lead to life-time signiﬁ  cant burdens on patients as well as family 
members and the society in general (Torrey 1995). Medication non-compliance is a 
major concern in the treatment of acutely ill psychiatric patients. Studies indicate that 
treatment failure is often linked to non-compliance (Soskis 1978; Cooper et al 2007). 
Different application forms other than conventional tablets may help to improve a 
patient’s compliance. New formulations of established antipsychotic medication 
have recently emerged that should extend the utility and ﬂ  exibility of administration 
and treatment (Caine 2006). The orally disintegrating tablet (ODT) formulation of 
olanzapine (Zydis® in the US and Velotab® in Europe, available in Germany since 2000) 
may provide an alternative means of treating non-compliant patients as well as those 
patients, who are either unable or reluctant to swallow a tablet, as ODT is designed to 
dissolve upon contact with saliva. Corresponding formulations are available for other Patient Preferences and Adherence 2007:1 20
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antipsychotics, eg, risperidone or aripiprazole. In a small study 
of schizophrenic patients, the mean disintegration time of ODT 
was 15.8 seconds, and subjective comments of the patients 
indicated high medication acceptance due to convenience 
of intake and subjective impression of effectiveness (Chue 
et al 2002; Bergstrom et al 2004). Removal of ODT from the 
tongue is also more difﬁ  cult than for the standard (coated) 
olanzapine tablet (SOT) since it forms an amorphous residue 
that can only be removed by scraping the tongue. The use 
of orally disintegrating tablets in other indications (eg, 
migraine, depression), has been successfully tested in other 
studies (Dowson et al 2002; Behnke et al 2003). Improved 
compliance has, besides improved cognitive functioning and 
reduced negative symptoms, also been identiﬁ  ed as a possible 
factor leading to a decrease in suicidality (Meltzer et al 
1998). In comparison to haloperidol, olanzapine decreased 
the suicide rate after one year of treatment in a clinical trial 
(Glazer 1998). Little information is available on the effect of 
olanzapine on suicidal ideation from large naturalistic studies 
although safety and effectiveness of olanzapine in acutely ill 
and ﬁ  rst-episode schizophrenic patients has been investigated 
in observational studies previously (Alvarez et al 2003; Bobes 
et al 2003). In the present study, we aimed to evaluate the use 
of ODT and SOT in a real-life setting with regard to patterns of 
use, patient types treated, treatment outcomes, and medication 
compliance. The effectiveness was assessed and documented 
by physicians using the Global Clinical Impression – Severity 
(CGI-S) and CGI – Improvement (CGI-I) scale as well as 
the MADRS suicidality item (Item #10), and nursing global 
impression (NGI), and medication acceptance was assessed 
by nursing staff. The study duration was 2 weeks to document 
primarily the short-term effects of the pharmacological 
intervention by the initially treating physician and nursing 
staff team in acute psychiatric emergency wards. Since 
clinical trials are conducted using experimental conditions 
and results can often not be generalized to normal clinical 
practice, the present study was undertaken and conducted in 
a naturalistic setting.
Methods
Patient population and study design
This was a prospective, multicenter naturalistic study of 
standard (coated) olanzapine tablets (SOT) and olanzapine 
disintegrating tablets (ODT) in adult male or female patients 
arriving at the 24-hour emergency-service of psychiatric 
care hospitals with a diagnosis or tentative diagnosis of acute 
schizophrenia. The objective of this study was to observe the 
use of SOT and ODT with regard to effectiveness (deﬁ  ned as 
efﬁ  cacy in the context of a natural setting), safety, and course 
of acute psychotic disease under naturalistic conditions.
The study involved 94 general and psychiatric hospitals 
located throughout Germany, and was conducted from 
October 2001 until July 2002. A median of 5 patients were 
documented per hospital (mean 5, range 1–15). Patients with 
hospital admission for other reasons than acute therapy (eg, 
transferred from another hospital subsequent to acute therapy 
or for elective adjustment of medication) were not eligible for 
participation. All data were collected anonymously and in full 
compliance with German Privacy Law regulations. All types 
of treatment observed were routinely available to German 
psychiatric emergency wards. The assessed medications were 
not provided by the manufacturer, but prescribed in the con-
text of clinical routine care. As no speciﬁ  c treatments were 
classiﬁ  ed for the observation, and the choice of therapy as 
well as switching between application forms was completely 
at the physician’s discretion, this study reﬂ  ects standard care 
in Germany. According to German legislation, no informed 
consent was needed for this observational study. For cor-
rect and complete documentation of data and for adverse 
event reporting, participating physicians received adequate 
reimbursement in accordance with the GOÄ (German phy-
sician fee schedule) in the amount of  150 per completely 
documented patient.
Assessments
Criteria for the evaluation of effectiveness were Clinical 
Global Impression – severity (CGI-S) (Guy 1976) at start 
of treatment and at ﬁ  nal documentation (14 days), Clinical 
Global Impression – Improvement (CGI-I) at ﬁ  nal documen-
tation (14 days). Suicidality was assessed by the Montgomery 
Asberg Depression Rating Scale (MADRS) item 10 (suicidal 
ideation) (Montgomery and Asberg 1979) at baseline and 
at ﬁ  nal documentation (14 days). CGI and MADRS item 
10 were completed by the physician. Patients’ medication 
acceptance and attitude towards olanzapine medication was 
assessed by the Nursing Assessment of Medication Accep-
tance (NAMA) questionnaire (Kinon et al 2003) to be 
completed by the nursing personnel at baseline and at ﬁ  nal 
observation. Tolerability was assessed as the incidence and 
type of adverse events reported. Patient characteristics and 
medical history (type of disease) were also documented.
Statistical analysis
The statistical analysis was carried out using SAS®, Version 
8.2 (SAS Institute Inc). All efﬁ  cacy parameters were evalu-
ated based on the full analysis set (intent to treat population), Patient Preferences and Adherence 2007:1 21
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ie, patients with at least one dose of olanzapine and at least 
one post baseline value available. Data are presented as means 
with their standard deviations (mean ± SD) unless otherwise 
indicated. Furthermore, 95% conﬁ  dence intervals (CI) were 
calculated without any correction for multiplicity. Sample sizes 
may vary because of missing values for certain parameters.
It was planned to observe 480 patients treated with olan-
zapine. This allows detection of an adverse event with an 
incidence of 0.6% at least once during the observation with 
a probability of 0.95. In order to compare the outcomes of 
patients treated with the two formulations after 2 weeks, the 
probability of having a better score (CGI-S, CGI-I, MADRS 
item 10) ODT vs SOT was calculated as relative effect using 
non-parametric methods (Brunner et al 2002). These methods 
are generalizations of the Wilcoxon-Mann and Whitney test 
(U-test) and the relative effect is the measure used by the 
U-Test. If one assumes Gaussian distribution of data, the 
relative effect is a function of the effect size, ie, a relative 
effect of 50% corresponds to an effect size of 0 standard 
deviations. A relative effect of more than 50% would indicate 
better scores for ODT compared to SOT at 2 weeks, whereas 
a relative effect below 50% would mean that the probability 
of observing a better score for ODT is lower. If Cohen’s sug-
gestions regarding small (d = 0.2), medium (d = 0.5), or large 
(d = 0.8) effect sizes in the case of normal distribution are 
applied to relative effects, a relative effect would be called 
small, medium, or large if they are larger than 0.556, 0.635, 
or 0.714, respectively (Brunner and Munzel 2002). Negative 
effect sizes of d = –0.2, d = –0.5, and d = –0.8 correspond 
to relative effects of 0.444, 0.362, and 0.286, respectively. 
The advantages of the relative effect over the effect size are 
the independence from the assumption of normal distribu-
tion, the correct description of ordered categorical data, and 
the interpretation as a simple probability. 95% CIs for the 
relative effects were calculated (Brunner et al 2002). The 
relative effects for CGI-S and MADRS item 10 were calcu-
lated within strata deﬁ  ned by the respective baseline value 
to reduce the bias introduced by the non-randomized design. 
However, due to the small sample sizes in some strata it was 
not possible to adjust for further confounding variables (eg, 
study site).
Results
Patient characteristics
Overall, 456 patients were documented prospectively in this 
observational study. 32 patients (7.0%) had discontinued 
the therapy prematurely (physician information), primar-
ily because of a change of therapy (18/32), the occurrence 
of an adverse event (3/32), and for other reasons such as 
dismissal or referral to another hospital (11/32). The major-
ity of patients was female (250 out of 456, 54.8%). Patient 
demographics are summarized in Table 1.
Patients’ age ranged from 18 to 93 years with a median 
age of 38 years, and with females on average being older 
than males. More than 80% of the patients documented 
(366, 80.3%) were treated because of schizophrenia or 
schizotypal and delusional disorders. Further underlying dis-
eases reported were mood (affective) disorders (79, 17.3%), 
organic disorders including symptomatic mental disorders 
(45, 9.9%), disorders of adult personality and behaviour 
Table 1 Baseline characteristics of patients treated with olanzapine disintegrating tablets or standard olanzapine tablets
Characteristic   SOT  ODT
   (N  = 207)  (N = 247)
Age (years)  Mean (±SD)   41.1  (±15.6)   41.2  (±15.8)
  Median   38.0   38.0
  Range   18.0–87.0   18.0–93.0
Sex, n (%)   Male  101 (49.0%)  105 (42.4%)
  Female  106 (51.0%)  142 (56.8%)
Duration of   Mean (±SD)     6.1  (±7.1)    8.5  (±9.4)
disease  (years)  Median    3.0    5.0
Disease type,  Schizophrenia, schizotypal,   159 (76.8%)  205 (83.0%)
n (%)  delusional
  Mood (affective) disorder    51 (24.6%)    28 (11.3%)
  Organic   20  (9.7%)   24  (9.7%)
  Disorders of adult personality    18 (8.7%)    20 (8.1%)
  Mental and behavioral disorders      10 (4.8%)    11 (4.5%)
  due to psychoactive substance abuse
Abbreviations: ODT, orally disintegrating olanzapine tablet; SOT, standard-coated olanzapine tablet; SD, standard deviation.Patient Preferences and Adherence 2007:1 22
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(38, 8.3%), and mental and behavioural disorders due to 
psychoactive substance abuse (21, 4.6%).
Physicians were free to decide which oral olanzapine 
formulation to use. For 207 (45.4%) patients, SOT was 
documented as initial treatment, and 247 (54.2%) patients 
started with ODT. For 2 patients, the olanzapine formulation 
used was not documented. No major differences were seen 
in the patients’ demographic characteristics when comparing 
the two cohorts (see Table 1). However, the results indicate 
that patients’ disease characteristics played a major role in 
determining the type of tablet given. Patients receiving ODT 
presented on average with a slightly longer mean duration 
of the disease. ODT was preferred for patients with agitated 
behaviour (externally-directed aggression, institutionalization, 
and psychomotor excitement), whereas the SOT was preferred 
for patients with psychomotor inhibition (see Figure 1).
Dosage and concomitant medications
The lowest daily dose documented was 2.5 mg, whereas the 
maximum daily dose was 40 mg for SOT and 60 mg for 
ODT. The average daily dose increased from 13.0 ± 6.9 mg at 
baseline to 16.9 ± 7.8 mg for SOT after the 2-week observational 
period. The mean dosage in patients receiving ODT started at 
14.1 ± 6.9 mg at baseline and increased to 18.2 ± 7.7 mg after 
2 weeks. The percentage of patients receiving high doses of 
olanzapine (ie, 20 mg/day) increased from approximately one 
third at baseline to around 50% at the last daily dose documented 
in the study. At baseline, 24.2% SOT patients received a high-
dose, compared to 41.1% after 2 weeks of treatment. The 
proportion of ODT patients receiving a high-dose increased 
from 34.4% at baseline to 59.1% after 2 weeks.
Patients in both groups (SOT and ODT) had received 
antipsychotic medication before the study (43.5% and 39.3%, 
respectively). More than 75% of all acutely treated patients 
received a psychotropic co-medication during the obser-
vational study. The most commonly taken co-medications 
were benzodiazepines/tranquilizers (58.6% of patients), other 
antipsychotics (typicals 25.2%, risperidone 0.7%, quetiapine 
0.7%, amisulpride 0.2%) and antidepressants (19.1% of 
patients). Anticonvulsants were used in 8.1% of patients.
Clinical Global Impression (CGI)
The change in disease severity (CGI-S) is shown in Table 2 
for patients treated with SOT vs ODT.
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Figure 1 Patient baseline disease characteristics by application form (coated tablets vs orally disintegrating tablets).Patient Preferences and Adherence 2007:1 23
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In patients receiving both formulations disease severity 
decreased, measured as CGI-S rated by the physician, inde-
pendent of dosage group after 2 weeks of treatment. The 
proportion of patients treated with SOT who were at least 
severely ill was reduced from 49.8% at baseline to 5.3% 
after 2 weeks of treatment. The respective results for patients 
treated with ODT were 64.4% at baseline and 15.0% after 
2 weeks (Table 2). In parallel, global impression of disease 
severity evaluated by the nursing staff (NGI-S) led to com-
parable results.
An improvement in disease severity from baseline 
(CGI-I categories improved, much improved, or very much 
improved) was documented for 92.1% of patients by the 
physicians (91.8% for patients treated with SOT, 92.3% for 
patients treated with ODT). Assessment of improvement 
conducted by nursing staff (NGI-I) produced comparable 
results.
The proportion of patients with an improved disease 
severity (CGI-I) was comparable between low-dose (20 
mg/day, 91.5%) and high-dose (20 mg/day, 92.7%) olan-
zapine treatment subgroups.
Relative effects analyses (ODT vs SOT) were performed 
on CGI-I and CGI-S data. The CGI-S analysis was stratiﬁ  ed 
by CGI-S baseline severity. Relative effects of ODT com-
pared to SOT for these parameters are summarized with 95% 
conﬁ  dence intervals in Table 3.
A high (0.5) relative effect would indicate a better 
outcome for ODT treated patients compared to SOT treated 
patients. Generally, relative effects were close to 0.5 with 
95% CI encompassing 0.5, indicating no differences in docu-
mented effectiveness in clinical practices. The only relative 
effect not encompassing 0.5 was seen for CGI-S in the 30 
patients with extremely severe baseline disease (CGI-S = 7) 
for which a lower relative effect for ODT was found. A 
larger proportion of these extremely acute patients receiving 
ODT were institutionalized and showed externally directed 
aggression (50%, 11/22), whereas these characteristics were 
present in only 25% (2/8) of the SOT patients, respectively. 
These extremely ill and institutionalized/ externally aggres-
sive patients had a lower probability for short-term treatment 
response.
Suicidal thoughts
Overall, there were 240 (52.6%) patients with some degree 
of suicidal ideation at baseline as measured by MADRS item 
10, including 30 patients (6.6%) with distinct suicidal plans. 
Data were missing for 12 (2.6%) patients. Suicidality ratings 
decreased from baseline to ﬁ  nal observation (2 weeks) in 189 
out of 456 patients (41.5%) and increased in only 2 patients 
(0.4%). As Figure 2 shows, the proportion of patients with 
any suicidal thoughts decreased from 51.2% and 53.9%, 
respectively at baseline to 22.7% and 20.6% after 2 weeks 
of treatment for SOT and ODT, respectively. No patients 
with distinct suicidal plans were observed after 2 weeks of 
treatment.
The non-parametric analysis using relative effects did not 
reveal consistent differences in suicidality rating improve-
ments between patients treated with ODT and SOT.
Analysis of changes in suicidality by treatment dose 
revealed no apparent differences between patients receiving 
either high-dose or the low-dose olanzapine treatment. The 
proportion of patients with decreased suicidality was 44.2% 
after 2 weeks for the low-dose treatment and 38.8% for the 
high-dose treatment.
Medication acceptance
Four dimensions of medication acceptance by the patient were 
assessed with the NAMA questionnaire: attitude (patient has 
Table 2 Disease severity (CGI-S) of patients treated with orally disintegrating olanzapine tablet or standard-coated olanzapine tablet 
at baseline and ﬁ  nal visit (Day 5, LOCF)
CGI-S SOT        ODT
  Baseline   Final  visit   Baseline    Final  visit
Physician  assessment  N  % N  % N  %  N  %
Borderline  ill  (2)   0  0   9  4.3    0  0   7  2.8
Mildly ill (3)    2  1.0  32  15.5      0  0  25  10.1
Moderately  ill  (4)  13  6.3 92 44.4   10 4.1  97  39.3
Markedly ill (5)  89  43.0  63  30.4    78  31.6  81  32.8
Severely ill (6)  95  45.9    8  3.9  137  55.5  29  11.7
Extremely ill (7)    8  3.9    3  1.5   22  8.9   8  3.2
Abbreviations: CGI-S, Clinical Global Impression, Severity; ODT, orally disintegrating olanzapine tablet; SOT, standard-coated olanzapine tablet; LOCF, last observation 
carried forward.Patient Preferences and Adherence 2007:1 24
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a positive attitude towards medication), compliance: (patient 
complies with medication intake), ingestion (patient ingests 
medication), and nursing (no extensive nursing effort is 
needed to administer medication). Proportions of positive 
assessment (applies very much, applies) for medication 
acceptance questions are shown for baseline and ﬁ  nal assess-
ments after 2 weeks in Figure 3.
At baseline, medication acceptance by the patient was lower 
in patients treated with ODT, in particular regarding attitude 
(SOT 58.0%, ODT 31.6%), ingestion (SOT 75.4%, ODT 
48.9%), and nursing (SOT 81.1%, ODT 53.9%). After 2 weeks, 
medication acceptance improved for both formulations, in par-
ticular for ODT (attitude SOT 78.3%, ODT 68.4%; ingestion 
SOT 89.4%, ODT 83.4%; nursing SOT 92.8%, ODT 86.2%).
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Figure 2 Patients with suicidal thoughts according to MADRS Item 10.
0 = Enjoys life or takes it as it comes.
2 = Weary of life. Only ﬂ  eeting suicidal thoughts.
4 = Probably better off dead. Suicidal thoughts are common, and suicide is considered as a possible solution, but without speciﬁ  c plans or intention.
6 = Explicit plans for suicide when there is an opportunity.   Active preparations for suicide.
Table 3 Relative effects in Clinical Global Impression Improvement (CGI-I) and Clinical Global Impression Severity (CGI-S) improve-
ment by baseline CGI-S for orally disintegrating olanzapine tablet compared to standard-coated olanzapine tablet
    Final visit (2 weeks)
    Relative effect  95% conﬁ  dence interval
 Baseline    lower  upper
CGI-I (n = 454) 0.5085  0.4587  0.5584
CGI-S  ≤4 (n = 25) 0.6233  0.4110  0.8355
 5  (n = 167) 0.4784  0.3967  0.5601
 6  (n = 232) 0.4338  0.3626  0.5050
 7  (n = 30) 0.2159  0.0161  0.4158
Abbreviations: CGI-I, Clinical Global Impression, Improvement, CGI-S, Clinical Global Impression, Severity; ODT, orally disintegrating olanzapine tablet; SOT, standard-
coated olanzapine tablet.Patient Preferences and Adherence 2007:1 25
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Safety
No deaths or serious adverse events were reported dur-
ing this study. A total of 23 (5.0%) patients experienced 
adverse events, and in 21 of these patients adverse events 
were considered as related to olanzapine treatment by the 
investigator (including not assessable and missing). The 
proportion of reported adverse events in patients receiving 
ODT was higher compared to patients receiving SOT (6.5% 
vs 2.9%, respectively).
The majority of the 28 adverse events documented in 
23 patients were either of mild (50.0%, 14/28) or moderate 
(46.4%, 13/28) severity and only one adverse event (3.6%) 
was considered as severe. In most cases patients recovered 
from their adverse events (60.7%, 17/28), whereas 25.0% 
(7/28) of events were not yet recovered by the end of the 
observation. The most frequently reported preferred term was 
weight gain (2.0%, 9/456 for all patients; 1.0%, 2/207 for 
SOT; 2.8%, 7/247 for ODT). Other adverse events reported 
in more than one (but in less than 1.0%) patient were tired-
ness, extrapyramidal symptoms, vertigo, and nausea. Three 
patients (0.7%, 3/456) discontinued prematurely because of 
an adverse event; they presented with an allergic reaction, an 
increase in creatinine kinase levels, and onset of restlessness 
(all of moderate intensity), respectively. All 3 received the 
ODT formulation.
Discussion
The objective of this study was to evaluate the use, effec-
tiveness and tolerability of orally disintegrating olanzapine 
tablets (ODT) and standard (coated) olanzapine tablets (SOT) 
in patients admitted to psychiatric hospitals for emergency 
treatment. For the current study, effectiveness was deﬁ  ned 
as efﬁ  cacy in the context of a natural setting.
Limitations of this prospective, open label study include 
the lack of randomization regarding the effectiveness 
comparisons, the frequent use of concomitant medications 
in a naturalistic setting, and a probable underreporting of 
adverse events in clinical practice compared to clinical tri-
als. Besides, only patients who actually took oral medication 
could be assessed. Information about the rate of rejections 
or forced use of oral medication is not available. Finally, 
patients are described as using ODT or SOT based on the 
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Figure 3 Patients with positive medication acceptance as rated by nursing personnel at baseline and ﬁ  nal documentation (2 weeks).
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formulation they started with. No data are available if any 
patients switched to the other formulation during the 14-day 
observation period.
However, acknowledging these limitations, the natural-
istic design provides a unique method of collecting informa-
tion on use patterns and effectiveness in the clinical setting 
without the artefacts of an experimental intervention, in 
particular, as the patients observed receive acute treatment, 
for which only limited data from randomized clinical trials 
are obtainable.
Of particular interest in this study was the comparison of 
treatment patterns and medication acceptance with the two 
different oral olanzapine formulations (ie, either SOT or 
ODT). Major differences were found in patient characteris-
tics, indicating that externally aggressive patients and those 
referred to inpatient treatment from 24-hour emergency ser-
vices of psychiatric care hospitals (institutionalized patients), 
ie, those thought to refuse their antipsychotic medication, 
were preferably treated with ODT. Furthermore, patients 
treated with ODT received on average higher doses of olan-
zapine during the observation and were more severely ill at 
baseline. Therefore, in current clinical practice in Germany, 
acutely ill psychiatric patients receiving olanzapine are more 
commonly treated with ODT if they appear more severely 
ill and/or aggressive.
Although these differences in baseline characteristics 
are present, the results of the present study indicate that 
patients treated with SOT and ODT show similar short-
term (2-week) effectiveness in the treatment of psychiatric 
emergency patients with schizophrenia and related disorders 
in clinical practice.
The rating of medication acceptance (Figure 3) shows 
that ODT is preferably given to patients with a negative 
attitude towards medication and who are, therefore, at risk 
of being non-compliant, but still can be persuaded to accept 
oral medication. During the ﬁ  rst 2 weeks of treatment, 
patients’ attitude towards medication improved, particularly 
in the ODT cohort. Successful use of ODT in acutely non-
compliant schizophrenic patients has already been reported 
for 85 patients in a controlled clinical trial (Kinon et al 2003). 
Prescription data gathered in the UK (Johnson et al 2002) 
suggest that olanzapine orally disintegrating tablets are fre-
quently used as a treatment alternative to depot neuroleptics 
in patients with compliance problems.
Several studies suggested that clozapine and olanzapine 
improve suicidality in schizophrenic patients (Meltzer et al 
1995; Beasley et al 1998; Meltzer et al 2003). Factors lead-
ing to a decrease in suicidality associated with clozapine or 
olanzapine may be improved cognitive function, reduced 
negative symptoms, and improved compliance. The results 
of the present study show that in patients treated with both 
olanzapine formulations suicidality (suicidal thoughts/ide-
ation) decreased to a similar extent, indicating that the orally 
disintegrating tablet may also be considered in the treatment 
of acutely ill schizophrenic patients with either self-directed 
(suicidal) or externally-directed aggression. Compared with 
conventional antipsychotics (eg, haloperidol), preliminary 
evidence suggests that atypical antipsychotics effectively 
reduce agitation, are better tolerated, and are associated with 
fewer adverse effects (Wright et al 2001; Breier et al 2002; 
Krakowski et al 2006; Marder 2006). In our study, the rate 
of adverse events reported in clinical practice was low and 
both formulations were well tolerated. However, the rate 
of adverse events was higher in patients receiving ODT 
compared to those receiving SOT. This may reﬂ  ect baseline 
differences in patient characteristics: ODT was preferably 
used in mostly aggressive patients with more severe clinical 
symptomatology at baseline. This may have contributed to 
the observed difference in reported adverse events.
A considerable proportion (50%) of the acutely ill 
psychiatric patients in this naturalistic study were treated 
with high doses (ie, 20 mg/day) of olanzapine. However, 
no major differences in treatment outcome or tolerability 
between these dose groups deﬁ  ned post-hoc were seen. Fur-
ther, no differences in the rate or type of adverse events were 
reported for patients who received low-dose vs high-dose 
olanzapine treatment. This is in line with several previous 
randomized controlled studies which have provided evidence 
for a safe and effective use of high-dose olanzapine in patients 
with severe acute and/or treatment resistant schizophrenia 
(Tollefson et al 2001; Volavka et al 2002; Baker et al 2003; 
Krakowski et al 2006). One recent randomized, double-blind 
controlled study has directly compared standard and higher 
doses of olanzapine (10 mg, 20 mg, 40 mg) in patients with 
acute schizophrenia and schizoaffective disorders (Kinon 
et al 2006). The results suggested that most individuals in the 
general population of patients with schizophrenia or schizoaf-
fective disorders will respond to the standard olanzapine dose 
range, but the use of higher doses may be warranted for a 
more severely ill patient population. A recent naturalistic 
study in 80 patients with severe agitation conducted in Spain 
also found signiﬁ  cant improvements on the PANSS-EC and 
Agitation-Calmness Evaluation scale (ACES) following a 
20 mg dose of olanzapine ODT. Treatment was well-tolerated 
and no serious treatment-emergent adverse events were 
observed (Pascual et al 2007). Our results nevertheless Patient Preferences and Adherence 2007:1 27
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demonstrate that in current clinical practice, high-dose 
treatment in patients with acute schizophrenia is common.
Conclusions
In conclusion, this non-randomized, observational study 
shows comparable outcomes and good tolerability in patients 
treated with both oral formulations of olanzapine. In an acute 
emergency setting, orally disintegrating tablets were prefer-
ably used for more severely ill and aggressive patients with 
low medication acceptance and were used in slightly higher 
doses compared to coated tablets.
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